10370sek
-0,4 %
Date:2024-04-26Time:17:29:52Latest report:Q4-2023List:Mid CapTicker:CALTX
Market Cap:6 178 msekEnterprise Value:6 171 msekNet Sales:1 207 msekEarnings:-466,2 msekEmployees:0ISIN:SE0010441584

Ratios

10-year key figure history for Calliditas Therapeutics turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Calliditas Therapeutics with index and moving average MA50 and MA200.

Stockprice:103,70
MA50:109,72
MA200:103,69
Price/MA200:0,0 %
RSI (14):44,6
Price/MA50:-5,5 %

Description

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.

Pharmaceuticals